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Introduction {#cam41256-sec-0001}
============

Aromatase inhibitors (AIs) are critical to the management of women with hormone receptor‐positive breast cancer (BC). Their use has evolved to include premenopausal women with high‐risk BC in combination with ovarian suppression [1](#cam41256-bib-0001){ref-type="ref"}, [2](#cam41256-bib-0002){ref-type="ref"}. Whether administered as monotherapy, sequential therapy, or extended therapy, AIs favorably impact disease free survival [3](#cam41256-bib-0003){ref-type="ref"}. However, AIs are also associated with a number of toxicities, of which arthralgia (AIA) is among the most common and significant.

The broad range of reported incidence of AIA (5--47%) may be attributed to a lack of uniformity in diagnostic criteria to define the condition and casual reporting [4](#cam41256-bib-0004){ref-type="ref"}. In two studies specifically designed to identify AIA, the incidence of AIA was consistently reported near 50%, and did not vary across different third‐generation AIs [5](#cam41256-bib-0005){ref-type="ref"}, [6](#cam41256-bib-0006){ref-type="ref"}. Importantly, AIA frequently results in noncompliance with AI regimens or treatment discontinuation entirely, both of which adversely impact clinical outcomes [5](#cam41256-bib-0005){ref-type="ref"}, [7](#cam41256-bib-0007){ref-type="ref"}.

Several clinical risk factors for AIA have been reported, including time since last menstrual cycle [8](#cam41256-bib-0008){ref-type="ref"}, obesity, prior hormone replacement therapy [4](#cam41256-bib-0004){ref-type="ref"} or chemotherapy, particularly taxanes [6](#cam41256-bib-0006){ref-type="ref"}. The relationship between low estrogen levels and arthralgias has been well reported [9](#cam41256-bib-0009){ref-type="ref"}. Niravath argues that an inflammatory intermediary is a driver of low estrogen and AIA [4](#cam41256-bib-0004){ref-type="ref"}. However, a precise predictor of women most at risk for developing AIA is not yet established.

Several studies have assessed a potential genomic link to AIA risk [10](#cam41256-bib-0010){ref-type="ref"}, [11](#cam41256-bib-0011){ref-type="ref"}, [12](#cam41256-bib-0012){ref-type="ref"}. Aside from a common methodological approach relying on prospective candidate gene or single‐nucleotide polymorphism (SNP) selection for study, these investigations' conclusions have varied. Despite such inconsistencies, we believe an alternative analytical approach may effectively identify germline mutations associated with an increased risk of moderate to severe forms of AIA. Furthermore, we believe gene attribution of these mutations might elucidate the pathophysiology underlying AIAs.

We devised a case--control study of women with early stage breast cancer with and without significant AIA. We favored methodology recognizing that risk amplification was more likely when groups of synergistically expressed SNPs occurred (rather than a single SNP) -- a departure from the 'magic bullet' approach. Consequently, we adapted a novel analytical method, previously proven to be effective in a smaller number of patients, to identify an optimum cluster of SNPs that when expressed together, differentiate those patients at risk for AIA [13](#cam41256-bib-0013){ref-type="ref"}.

Patients and Methods {#cam41256-sec-0002}
====================

After Institutional Review Board permission was obtained, a systematic chart review of women enrolled in The Columbus Breast Cancer Tissue Bank was completed to identify patients receiving first‐line adjuvant treatment with third‐generation AIs (anastrazole, exemestane, letrozole) for at least 1 month to treat stage I‐III estrogen receptor‐positive BC between 2003 and 2012. Clinical efficacy of endocrine therapy was not captured in this investigation. Concurrent gonadotropin‐releasing (GnRH) agonist therapy, radiation therapy, prior tamoxifen use, and/or chemotherapy were allowed. Patients with metastatic disease or active autoimmune or inflammatory joint disease were excluded. Patients were divided into two groups: those with clinically significant AIA (defined as grade 2 or above by NCI‐CTCv.4 criteria) and/or requiring modification or termination of AI therapy, and those without any reported clinical signs or symptoms of AIA.

Germline DNA was extracted from mononuclear cells at the Human Cancer Genetics Sample Bank, The Ohio State University, according to previously published protocol [14](#cam41256-bib-0014){ref-type="ref"}. DNA was quantitated using PicoGreen and 200 ng of each DNA aliquoted into 96‐well plates. After sample elimination for poor quality DNA, SNP genotyping was performed along with appropriate controls. DNA amplification, fragmentation, and hybridization to Axiom UK Biobank genotyping arrays (Affymetrix, Santa Clara, CA) was completed using Axiom Reagent Kits; hybridization, ligation, washing, staining, and scanning of the arrays was completed on the GeneTitan MC instrument (Affymetrix). Initial plate QC was performed using Affymetrix Genotyping Console Software, and genotype calling done using Affymetrix Power Tools (v1.15.0) with the Axiom GT1 algorithm, which is a modified version of the BRLMM‐P algorithm that adapts generic prior cluster positions to the data using an EM algorithm.

Analysis {#cam41256-sec-0003}
--------

To establish the parameters by which fold‐change thresholds were maximized to identify distinguishing SNPs, we considered SNPs in 3 groups: those uniquely associated with the AIA‐positive group, the AIA‐negative group, and those predominantly, but not uniquely associated with either group. We then assigned arbitrary numerical identifiers of 1, 2, or 3 to each group for parameterization and found that the maximum fold‐change defining a signal was log2 (3/1) = 1.59. Figure [1](#cam41256-fig-0001){ref-type="fig"} shows the flowchart of the methodology, which is composed of the following steps:

![Flowchart of the analytical steps used to identify those SNPs most predictive of AIA risk in the study population.](CAM4-7-240-g001){#cam41256-fig-0001}

Analysis of the discriminatory power of the SNPS {#cam41256-sec-0004}
------------------------------------------------

To identify the discriminatory power of those SNPs that were differentially noted between the AIA‐positive and ‐negative cohorts, we utilized a machine‐learning algorithm in which we combined fold change and Fisher\'s ratio. We defined the Fisher\'s ratio for a SNP *j* in a two‐class classification problem, *c* ~1~, *c* ~2~ as:$$\text{FR}_{j}{(c_{1},c_{2})} = \frac{{(\mathit{\mu}_{j^{1}} - \mathit{\mu}_{j^{2}})}^{2}}{\mathit{\sigma}_{j^{1}}^{2} + \mathit{\sigma}_{j^{2}}^{2}}$$where $\mathit{\mu}_{j^{1}}^{2}$ $\mathit{\mu}_{j^{2}}^{2}$ are measures of the center of the distribution (means) of prognostic variables *j* in classes 1 and 2 (AIA and no AIA), and $\mathit{\sigma}_{j^{1}}^{2}$, $\mathit{\sigma}_{j^{2}}^{2}$ are measures of the dispersion (variance) within these classes. This method is particularly effective for identifying prognostic/predictive variables that separate the classes further apart and are very homogeneous within classes (low intraclass variance).

We considered the 1% tail of the fold change (over and underexpressed SNPs), providing a final set of 436 high discriminatory SNPS with fold change in the interval \[−0.31, 0.22\] and Fisher\'s ratio greater than 1.5.

Finding the small‐scale SNPs signature {#cam41256-sec-0005}
--------------------------------------

Once we identified those SNPs differentiating AIA‐positive and ‐negative patients, we ranked them in decreasing order based on their discriminatory power. Hypothesizing that optimization of predictive risk determination is most accurately the consequence of a collective effect from a cluster of SNPs, we then sought to identify the smallest aggregate of SNPs with the highest prognostic accuracy using an algorithm based on recursive elimination of lower discriminatory SNPs. Our analysis was based on the fact that high discriminatory variables served to span the main features of the classification (AIA), while the variables with lowest discriminatory ratios were of such granularity as to not markedly contribute to being informative as to differential risk. This method determined the minimum amount of high‐frequency details required to optimally discriminate between classes. The predictive accuracy estimation was based on Leave‐One‐Out‐Cross‐Validation (LOOCV) [10](#cam41256-bib-0010){ref-type="ref"}, [11](#cam41256-bib-0011){ref-type="ref"} given our goal to estimate how accurately the predictive model (classifier) would perform for future samples with an unknown AIA status.

Stability analysis of the small‐scale signature {#cam41256-sec-0006}
-----------------------------------------------

By random 75--25 hold‐out experiments, we next evaluated the stability of the small‐scale signatures' predictive accuracy (i.e., AIA contributions) found via LOOCV when the number of training samples was decreased. Due to absence of a totally independent clinical data set, the minimum‐scale signature was read in the training dataset for training (75% of the whole set) and applied for blind validation in the validation set (25%). The cumulative distribution function of the small‐scale predictive accuracies found in different hold‐outs was finally presented and accounted for the variability in its predictive accuracy with partial information. An additional statistical analysis was performed to provide the minimum, maximum, and median bounds that could be expected in an independent dataset. Figure [2](#cam41256-fig-0002){ref-type="fig"} shows the cumulative probability function of the predictive accuracy of the small‐scale signature obtained after 5000 random simulations.

![Stability analysis of the small‐scale signature of the 70 SNPs which were identified as being most predictive of AIA risk. The figure shows the cumulative distribution function of the predictive accuracy obtained after 5000 random 75/25 hold out simulations. It can be observed that the median accuracy (percentile 50) is around 75%, being the lower and upper‐quartiles 71% and 78%. The minimum and maximum accuracy achieved was 54% and 100%.](CAM4-7-240-g002){#cam41256-fig-0002}

Random sampling of high predictive SNPs equivalent networks {#cam41256-sec-0007}
-----------------------------------------------------------

We next used a random sample to find other networks of highly discriminatory, prognostic SNPs. As the prior sampling probability of any individual SNP was considered to be proportional to its Fisher\'s ratio, we preferentially sampled the most discriminatory SNPs. To look at the impact of SNP synergism in enhancing risk prediction, we developed the most discriminatory networks and analyzed the posterior sampling frequencies of the main prognostic variables involved in each network. The analysis was completed by establishing the correlation network among the most discriminatory SNPs. The network was built using the maximum spanning tree algorithm (an acyclic graph that maximizes the value of the edges) and the Pearson correlation coefficient to identify those SNPS that showed the maximum positive and negative Pearson coefficient.

Gene attribution and functional analysis {#cam41256-sec-0008}
----------------------------------------

We employed two different databases, NCBI Phenotype‐Genotype Integrator (NCBI PheGenI) [15](#cam41256-bib-0015){ref-type="ref"} and Ensemble release 88 [16](#cam41256-bib-0016){ref-type="ref"} using Genome assembly: GRCh38.p9, to gather the genes and their functional consequences associated with the top 70 most discriminatory SNPs (not shown).

To assess the functional validity of the SNP‐associated genes, we performed a comprehensive literature review of each gene associated with the most predictive SNPs, and summarized all relevant phenotypic attributions linking them to the following phenotypes: "arthralgia," "synovial," "arthritis," "rheumatoid," "joint," "pain," "sensitization," and "nociception." This was done via an 'undirected' review of all publications citing each gene, which was accessed via GeneAnalytics GeneCards'[17](#cam41256-bib-0017){ref-type="ref"} "Publications" section for each gene of interest [18](#cam41256-bib-0018){ref-type="ref"}.

We next determined the presence of any linkage disequilibrium (LD) among the 70 most discriminatory SNPs, as it is plausible that SNPs that individually have marginal influence on arthalgia risk‐associated genes may be inherited in linkage, and together as a group, synergistically increase arthralgia risk. Linkage disequilibrium was assessed by querying the 70 SNPs using Broad Institute\'s SNP Annotation and Proxy Search (SNAP) tool in the CEU (Utah residents with Northern and Western European ancestry) with *R* ^2^ threshold of 0.8 and distance limit of 500 [19](#cam41256-bib-0019){ref-type="ref"}, [20](#cam41256-bib-0020){ref-type="ref"}.

As a final analysis of functional and phenotypic relevance of the gene set found to be influenced by the 70 SNPs, we applied an undirected assessment using GeneAnalytics software. We reasoned this would provide a relevance validation, but acknowledge the risk of overinterpretation of a small input. This program provides a semiquantitative output of gene cluster relationships relative to disease, pathway, and ontologic relationships. Relationships with "medium" and "high" matched scores for the diseases and pathways were reviewed.

Results {#cam41256-sec-0009}
=======

Systematic chart review of 700 AI‐treated patients with stage I‐III BC identified asymptomatic patients (*n* = 39) and those with clinically significant AIA resulting in AI termination or therapy switch (*n* = 123). There were no significant demographic or disease differences between the AIA‐positive and ‐negative cohorts. Patients were similar in age (controls: 58.6 years, cases: 58.2 year), stage at diagnosis, and estrogen receptor status (Table [1](#cam41256-tbl-0001){ref-type="table-wrap"}). After sample elimination for poor‐quality DNA, SNP genotyping was performed for 123 AIA positive and 39 AIA negative patients.

###### 

Comparative tumor characteristics of patients in the control (no AIA) and cases (clinically significant AIA) arms

                                    Controls (*N* = 39) (%)   Cases (*N* = 123) %
  --------------------------------- ------------------------- ---------------------
  Stage I                           22 (56)                   55 (45)
  Stage II                          14 (36)                   54 (44)
  Stage III                         3 (8)                     14 (11)
  ER or PR positive/HER2 negative   33 (85)                   104 (85)
  ER or PR positive/HER2 positive   6 (15)                    19 (15)
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Discriminatory SNPs {#cam41256-sec-0010}
-------------------

Germline DNA was obtained and SNP genotyping performed to yield 695,277 SNPs. The analysis confirmed the importance of the main discriminatory SNPs (Table [2](#cam41256-tbl-0002){ref-type="table-wrap"}). Using the filtering sequence, after we determined and rank ordered the most discriminatory SNPs (*n* = 400), we identified the smallest number of SNPs that were most predictive of risk using the LOOCV algorithm described above. This method\'s overall predictive accuracy was calculated by iterating all of the filtered samples. We found that a signature consisting of 70 specific SNPs had the highest predictive accuracy of 75.93% (Table [2](#cam41256-tbl-0002){ref-type="table-wrap"}). Analysis of the SNP signature\'s predictive accuracy (Figure [2](#cam41256-fig-0002){ref-type="fig"}) demonstrated a median accuracy and true positive rate of 75.6% with an interquartile range of 7.3% and a true negative rate of 76.2%. The predictive accuracy\'s mean and standard deviation was 74.6% and 5.8%, respectively. The minimum and maximum accuracy of these random holds was 54% and 100%, which implies that the minimum size signature of SNPs is quite stable. While we cannot analyze how this predictive signature would vary when new patient data is acquired, we hypothesize the result will be similar to that described by the hold‐out experiments.

###### 

The seventy SNPs that defined AIA risk within the study population, and their possible functional relevance

  SNP                         SNP Consequence                                                                           Impacted Gene     Gene\'s Relevant Phenotype Attributions                Evidence/Comments
  --------------------------- ----------------------------------------------------------------------------------------- ----------------- ------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  rs72765615                  Intron Variant, 3′ UTR Variant                                                            CHD2              --                                                     
  rs17149310                  Downstream Gene Variant                                                                   CFAP77            --                                                     
  rs8028334                   Intron variant                                                                            IL16              RA pathophysiology                                     Differentially elevated in synovial fluid from RA patients [25](#cam41256-bib-0025){ref-type="ref"}, [26](#cam41256-bib-0026){ref-type="ref"}, [44](#cam41256-bib-0044){ref-type="ref"}, [45](#cam41256-bib-0045){ref-type="ref"}, [46](#cam41256-bib-0046){ref-type="ref"}, [47](#cam41256-bib-0047){ref-type="ref"}, [48](#cam41256-bib-0048){ref-type="ref"} and mediates chemoattraction of CD4+ cells to synovial tissue [25](#cam41256-bib-0025){ref-type="ref"}, [26](#cam41256-bib-0026){ref-type="ref"}, [49](#cam41256-bib-0049){ref-type="ref"}, [50](#cam41256-bib-0050){ref-type="ref"}. However, IL16 correlation with clinical disease activity has been conflicting[45](#cam41256-bib-0045){ref-type="ref"}, [46](#cam41256-bib-0046){ref-type="ref"}.
  rs12004732                  Intron variant                                                                            PLAA              RA pathophysiology                                     Detected in high levels in RA synovial fluid [22](#cam41256-bib-0022){ref-type="ref"} and may have inflammatory roles [51](#cam41256-bib-0051){ref-type="ref"}. Intrathecal injection in rabbit joints results in inflammatory arthritis[21](#cam41256-bib-0021){ref-type="ref"}
  rs2883917                   Intron Variant                                                                            NR3C2             ‐ Pain sensitization‐ Fibromyalgia                     May be promote visceral hypersensitivity[36](#cam41256-bib-0036){ref-type="ref"}, and be implicated in pathophysiology of fibromyalgia[37](#cam41256-bib-0037){ref-type="ref"}
  rs61363926                  Noncoding Transcript Exon Variant                                                         BANF1P2           --                                                     
  rs56335940                  Intron Variant                                                                            LINC00882         --                                                     
  rs3749817                   Missense                                                                                  FSTL4             --                                                     
  rs879605                    Intron variant, upstream variant 2KB                                                      LTBR              RA pathophysiology                                     Induces RA synovial fibroblast proliferation and expression of inflammatory elements [28](#cam41256-bib-0028){ref-type="ref"}, [29](#cam41256-bib-0029){ref-type="ref"}. Associated with pain and disability in RA patients [27](#cam41256-bib-0027){ref-type="ref"}
  rs879605                    Intron variant, upstream variant 2KB                                                      SCNN1A            --                                                     
  rs986324                    Intron variant                                                                            PTCHD1‐AS         --                                                     
  rs7017819                   Intron variant, Noncoding Transcript Exon Variant                                         RP1L1             --                                                     
  rs12799692                  Intron variant                                                                            OPCML             --                                                     OPCML may bind opioids [52](#cam41256-bib-0052){ref-type="ref"}. It is also a tumor suppressor in and may be a marker of several types of tumors[53](#cam41256-bib-0053){ref-type="ref"}, [54](#cam41256-bib-0054){ref-type="ref"}
  rs4394668                   Intron variant                                                                            DHRS3             --                                                     
  rs10996945                  Intron variant                                                                            CTNNA3            --                                                     
  rs10996945                  Intron variant                                                                            LOC105378340      --                                                     
  rs705226                    Intron variant                                                                            LOC105374060      --                                                     
  rs73042968                  Intron Variant                                                                            FBLN2             Breast cancer pathophysiology                          Loss of FBLN2 expression is associated with breast cancer progression [55](#cam41256-bib-0055){ref-type="ref"}
  rs1546734                   Intron Variant                                                                            LOC105377150      --                                                     
  rs17270243                  Intron Variant                                                                            RORA‐AS1          --                                                     
  rs17270243                  Intron Variant                                                                            RORA\*            ‐ Breast cancer pathophysiology‐ Estrogen metabolism   ‐ May suppress breast tumor invasion by inducing SEMA3F[56](#cam41256-bib-0056){ref-type="ref"}.‐ \[Conflicting\] Is a transcriptional regulator of aromatase [57](#cam41256-bib-0057){ref-type="ref"}. Activates aromatase expression in breast cancer cells, likely contributing to proliferation [58](#cam41256-bib-0058){ref-type="ref"}
  rs5760686                   Intron Variant                                                                            SGSM1             --                                                     
  rs9907168                   Intron Variant                                                                            CDC42EP4          --                                                     
  rs76098632                  Intron Variant                                                                            FBXL17            Breast cancer marker                                   May be a potential biomarker for breast cancer therapy[59](#cam41256-bib-0059){ref-type="ref"}
  rs2243511                   Intron Variant                                                                            TMEM50B                                                                  
  rs2243511                   Intron Variant                                                                            IFNGR2            RA pathophysiology                                     ‐Significant differences in blood mononuclear cell expression of IFNGR2 was seen in African American RA patients with erosion and those with no erosion [30](#cam41256-bib-0030){ref-type="ref"}
  rs1012629                   Intron Variant                                                                            PTPRK             ‐ RA pathophysiology‐ Breast cancer pathophysiology    ‐Knocking down its encoded receptor impairs migration and invasiveness of RA fibroblast‐like synoviocytes (FLS), which otherwise progress to destroy cartilage and bone. This receptor mediates inflammatory signaling of TGF‐Beta in RA FLS [60](#cam41256-bib-0060){ref-type="ref"}.‐ Is a negative regulator of adhesion and invasion of breast cancer cells; its downregulation is associated with worse prognosis [61](#cam41256-bib-0061){ref-type="ref"}
  rs322960                    Intron Variant                                                                            TRPV3             Pain sensitization                                     ‐TRPV3 activation senses peripheral pain [24](#cam41256-bib-0024){ref-type="ref"}. It accumulates in peripheral nerves and dorsal root ganglion after injury [23](#cam41256-bib-0023){ref-type="ref"}.
  rs3743160                   Intron Variant, 5′ UTR Variant                                                            SLC28A1           Breast cancer pathophysiology                          SLC28A1 expression may be implicated breast cancer cell responsiveness to chemotherapy [62](#cam41256-bib-0062){ref-type="ref"}, [63](#cam41256-bib-0063){ref-type="ref"}
  rs797818                    Intron Variant                                                                            SEMA3A            ‐ RA pathophysiology‐ OA pathophysiology               ‐Reduced SEMA3A expression in human synovial tissues was associated with RA disease activity [31](#cam41256-bib-0031){ref-type="ref"}‐ SEMA3A expression is elevated in osteoarthritic cartilage, and inhibits VEGF\'s effects [64](#cam41256-bib-0064){ref-type="ref"}
  rs11670284                  Intron Variant                                                                            NLRP13            --                                                     
  rs2808787                   Intron Variant                                                                            COL27A1                                                                  \*Questionable relevance:‐ The temporal association and location of COL27A1 encoded collagen during calcification/transition of cartilage to bone suggests that the collagen is involved in the process. However, no specific roles have been elucidated [65](#cam41256-bib-0065){ref-type="ref"}.‐ A SNP in the region of COL27A1 (rs946053) occurred significantly more in a sample of patients with Achilles Tendinopathy, than in the control group [66](#cam41256-bib-0066){ref-type="ref"}.
  rs2215016                   Intron Variant                                                                            RGS6              --                                                     
  rs3766160 and rs3820071     Missense Variant                                                                          CELA2B            Poorly studied.                                        
  rs10511813                  Upstream variant 2KB                                                                      LOC105376002      --                                                     
  rs12127403                  Upstream Gene Variant                                                                     VHLL              Poorly studied.                                        
  rs10908495                  Missense, Noncoding Transcript Variant                                                    GLMP              --                                                     
  rs11683506                  Intron Variant                                                                            SMARCAL1          --                                                     
  rs6081792                   Intron Variant, Upstream Gene Variant                                                     RIN2                                                                     \*Questionable relevance:‐Deficiency of Encoded protein causes a congenital syndrome that includes severe joint hyperlaxity and scoliosis[67](#cam41256-bib-0067){ref-type="ref"}.
  rs1047312                   3′ UTR Variant                                                                            SULT1C2           --                                                     
  rs17011869                  Intron Variant                                                                            CNTNAP5           --                                                     
  rs818399                    Intron Variant                                                                            LINC00922         --                                                     
  rs11586047                  Intron Variant                                                                            LOC105371436      --                                                     
  rs28964                     Intron Variant                                                                            SPACA3            --                                                     
  rs10900269 and rs11239786   rs10900269 ‐ Intron Variant rs11239786 ‐ Noncoding Transcript Variant, Synonymous codon   BMS1              --                                                     
  rs11600377                  Noncoding Transcript Exon Variant                                                         MRGPRF‐AS1        --                                                     
  rs11600377                  Upstream Gene Variant                                                                     MRGPRF                                                                   \*Questionable relevance:‐ MRGPRF is a part of a family of proteins expressed in pain sensory neurons, and may be specifically activated by neuropeptides. However, MRGPRF, specifically, was not found in dorsal root ganglia in this study [68](#cam41256-bib-0068){ref-type="ref"}.
  rs62525208                  Intron Variant                                                                            C8orf37‐AS1       --                                                     
  rs61782448                  Intron Variant                                                                            PLEKHM2           --                                                     
  rs77413365                  Intron Variant                                                                            GRIA1             Inflammatory pain sensitization                        ‐ Trafficking of this Glutamate receptor in the central nervous system plays a role in inflammatory pain (TNF or IFN‐gamma mediated) and neuronal sensitization [34](#cam41256-bib-0034){ref-type="ref"}.‐ May also be implicated in inflammatory central sensitization of dorsal horn[33](#cam41256-bib-0033){ref-type="ref"}.‐Intrathecal injection of a painful inflammatory agent altered subcellular distribution of GRIA1, and decreased GRIA1 concentration in dorsal horn [32](#cam41256-bib-0032){ref-type="ref"}.
  rs1280408                   Intron Variant                                                                            CGNL1                                                                    \*Questionable relevance:‐The promoter of this gene may associate with the aromatase gene (due to a heterozygous inversion in chromosome 15q21.2‐3) to cause pathological aromatase and estrogen excess [69](#cam41256-bib-0069){ref-type="ref"}, [70](#cam41256-bib-0070){ref-type="ref"}.
  rs13013882                  Splice Region Variant, Synonymous Codon                                                   MROH2A            --                                                     
  rs17599018                  Intron Variant                                                                            GPM6A             Pain sensitization                                     ‐In cortical cultures of neurons, coexpression of GPM6A markedly increased the endocytosis of Mu‐type Opioid Receptors from plasma membrane to intracellular vesicles [35](#cam41256-bib-0035){ref-type="ref"}.
  rs2269767                   Intron Variant                                                                            UBFD1             Inflammatory antagonist                                ‐UBFD1‐encoded protein was identified as a polyubiquitin binder and may regulate NFkB activity through competitive antagonism of the NFkB pathway [38](#cam41256-bib-0038){ref-type="ref"}.
  rs7024415                   Downstream Gene Variant                                                                   ENSG00000253400   --                                                     
  rs1546734                   Intron Variant                                                                            ENSG00000242120   --                                                     
  rs4785496                   Upstream Gene Variant                                                                     ENSG00000260605   --                                                     

Seventy SNPs were identified which were associated with AIA risk. In addition to listing those SNPs, the consequence of each SNP is defined as is the gene most impacted by the mutation. Using literature mining as described in the Methods section, we determined the potential implication of genes relative to the development of AIA.
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The four most discriminating SNPs according to their sampling frequency as established by the random sampler were rs1462506, rs17149310, rs2883917, and rs10778060. The correlation network in Figure [3](#cam41256-fig-0003){ref-type="fig"} shows that the header SNP in the graph (rs7276615) is weakly, negatively correlated with rs11586047, rs6195687, rs10916270, and rs1462506. The main tree is developed under rs11586047, and the correlation coefficients are very low, suggesting that these SNPs are almost independent prognostic factors of the arthralgia phenotype. SNPS rs6195687, rs10916270, and rs1462506 are terminal nodes.

![Color visualization delineating the relationship of the 70 predictive SNPs and their functional relevance. (A) Correlation tree of the most discriminatory SNPs. This tree is built using the minimum spanning tree algorithm using the Pearson correlation coefficient. The algorithm looks for the maximum absolute values of the Pearson correlation coefficient (positive and negative correlations) within the set of most discriminatory SNPs. This hierarchical figure describes the strength of relationships between SNPs and how each SNP relates to the others in the cluster.(B) Associated phenotypes include similar phenotypes (RA, pain, inflammation and those associated with the tumor diagnosis).](CAM4-7-240-g003){#cam41256-fig-0003}

Functional validity and gene attribution {#cam41256-sec-0011}
----------------------------------------

To assess the potential functional validity of the 70 most predictive SNPs, we assessed gene attribution for each SNP and found that 57 genes were associated with the 70 SNPs of interest, with four genes linked to consequences from two or more SNPs (rs12004732 and rs7863476, variants of *PLAA*; rs322960 and rs60292929, variants of *TRPV3*; rs3766160 and rs3820071, variants of *CELA2B*, and rs10900269 and rs11239786, variants of *BMS1*). Assuming that an increase in the ratio of SNP to gene could suggest a more influential impact of arthalgia risk prediction by that gene, we evaluated the relationship between the aforementioned genes and arthalgia‐related phenotypes.

Following the search strategy defined above, we noted that both *PLAA* and *TRPV3* had relevant associations with arthalgia phenotypes. *PLAA* is implicated in inflammatory pathways of synovial cells from Rheumatoid Arthritis (RA) patients [21](#cam41256-bib-0021){ref-type="ref"}, [22](#cam41256-bib-0022){ref-type="ref"}, and caused inflammatory arthritis when injected into rabbit knee joints [21](#cam41256-bib-0021){ref-type="ref"}. *TRPV3* accumulates in peripheral nerves and dorsal root ganglion [23](#cam41256-bib-0023){ref-type="ref"}, and its activation is implicated in sensing peripheral pain [24](#cam41256-bib-0024){ref-type="ref"}. Associations of *CELA2B* are poorly understood. Lastly, there is no primary data to suggest a direct relationship between *BMS1*, arthralgias or BC, although *BMS1* is also poorly studied. The potential synergistic impact of these genes on AIA risk requires additional study.

In addition to the four genes above, 19 of the other 57 genes associated with the top 70 SNPs were linked to phenotypes involving BC, estrogen metabolism, and significantly, arthralgia. Some of these arthralgia associations include *IL16* (was significantly elevated in synovial fluid of RA patients and mediated chemoattraction of CD4 +  cells into synovial tissues [25](#cam41256-bib-0025){ref-type="ref"}, [26](#cam41256-bib-0026){ref-type="ref"}), *LTBR* (its expression in RA patients' synovium positively associated with pain and disability [27](#cam41256-bib-0027){ref-type="ref"}, and may be implicated in RA synovial fibroblast proliferation and expression of inflammatory elements [28](#cam41256-bib-0028){ref-type="ref"}, [29](#cam41256-bib-0029){ref-type="ref"}), *IFNGR2* (joint erosion, joint space narrowing, and disease progression was significantly associated with differential expression of *IFNGR2* in blood mononuclear cells of African American RA patients with radiographic erosion compared to patients with no erosion [30](#cam41256-bib-0030){ref-type="ref"}), *SEMA3A* (expressed in synovial tissues and associated with RA [31](#cam41256-bib-0031){ref-type="ref"}), *GRIA1* (implicated in inflammatory pain and central sensitization of dorsal horns [32](#cam41256-bib-0032){ref-type="ref"}, [33](#cam41256-bib-0033){ref-type="ref"}, [34](#cam41256-bib-0034){ref-type="ref"}), *GPM6A* (associated with endocytosis of Mu‐type opioid receptors in neuronal cortical cell cultures [35](#cam41256-bib-0035){ref-type="ref"}), *NR3C2* (may promote visceral hypersensitivity [36](#cam41256-bib-0036){ref-type="ref"} and may be implicated in pathophysiology of fibromyalgia [37](#cam41256-bib-0037){ref-type="ref"}), and lastly, *UBFD1* (implicated as a regulator of NFkB pathway [38](#cam41256-bib-0038){ref-type="ref"}) (Table [2](#cam41256-tbl-0002){ref-type="table-wrap"}).

Linkage disequilibrium {#cam41256-sec-0012}
----------------------

The LD analysis found 3 sets of SNPs among the top 70 SNP to be in LD. The first LD pair included rs3766160 and rs3820071, missense mutations of *CELA2B*, a poorly characterized gene. The second pair includes LD between rs12127403 (Upstream Gene Variant of *VHLL*, which competetively prevents degradation of HIF‐alpha [39](#cam41256-bib-0039){ref-type="ref"}) and rs10908495 (a variant of *GLMP*, another poorly characterized gene). The last pair consisted of rs3011665 and rs981360, which are not known to consequence any specific genes.

Discussion {#cam41256-sec-0013}
==========

AIA is a prevalent and disrupting toxicity of AIs, impacting quality of life, adherence and clinical outcomes [40](#cam41256-bib-0040){ref-type="ref"}. As with other regimen‐related toxicities, the risk for AIA is not consistent among patients receiving identical treatments for the same disease. The ability to prospectively differentiate patients at risk for AIA would be desirable at a number of levels, but most importantly in providing actionable data that could inform clinician and patient decision‐making, as well as leading to the design of intervention trials focused on high‐risk individuals. Additionally, the identification of a predictive biomarker strongly associated with a clinically meaningful manifestation of AIA could provide a surrogate for its more accurate reporting.

To identify the SNPs of interest, we used a machine‐learning algorithm for which the SNPs of interest were not pre‐determined. Rather, employing a previously validated technique, we used a filtering step to create a hierarchal list of SNPs most associated with the AIA phenotype while simultaneously eliminating SNPs that were simply genomic "noise" [13](#cam41256-bib-0013){ref-type="ref"}. We were able to reduce nearly 400,000 SNPs by three logs to approximately 450 SNPs. We then asked which SNPs were most predictive as a 'team' and, using a method in which we sequentially tested every combination of SNPs, identified 70 SNPs that collectively predicted AIA with fair accuracy (75.93%).

Attempts to determine AIA risk‐based strictly on demographic features have been only marginally successful. We found no differences in the study cohorts' clinical or demographic characteristics. The application of genomic markers, particularly SNPs, as a means to assess toxicity risk associated with cancer treatment regimens has been studied broadly, but with wide ranging and often inconsistent results. In general, two approaches have been used: candidate gene or SNP studies and GWAS. Investigations of genomic risk factors for AIA have exclusively depended on candidate gene/SNP identification.

Since *CYP19A1* codes for the aromatase enzyme in postmenopausal women, it has been an obvious candidate gene for AIA risk prediction [41](#cam41256-bib-0041){ref-type="ref"}. While three studies have studied polymorphisms associated with *CYP19A1* relative to AIA and found an association, there is variability in the SNPs reported [12](#cam41256-bib-0012){ref-type="ref"}, [41](#cam41256-bib-0041){ref-type="ref"}, [42](#cam41256-bib-0042){ref-type="ref"}, [43](#cam41256-bib-0043){ref-type="ref"}. Other polymorphisms associated with estrogen and vitamin D metabolism have also been targeted. While analyzing such SNPs for risk prediction, Garcia‐Giralt and her colleagues introduced multiplicative terms into their analysis, thus providing a conceptual basis for synergism in contributing to AIA risk [12](#cam41256-bib-0012){ref-type="ref"}. In a related investigation, Lintermans et al. reported that a SNP associated with the osteoprotegrin gene was associated with adverse symptoms (hot flashes and pain) in patients treated with AIs [10](#cam41256-bib-0010){ref-type="ref"}.

A drawback of candidate gene studies is that they limit discovery of phenotype‐associated genes or SNPs that may not be obvious to investigators deciding on targets. Analogous to trying to describe a landscape in the dark by shining a flashlight with a narrow beam, candidate gene studies may miss important features. Consequently, we took an analytical approach that differed from conventional paradigms in three important ways: (1) we did not mandate a threshold gene expression (SNP) level change for inclusion; (2) we evaluated simultaneous expression of SNP profiles (clusters); (3) the predictive clusters that evolved were driven by their collective and hierarchical relationships with the study groups rather than dependent on preconceptions of an expected result. Importantly, we were able to confirm the relevance of the discovered clusters by confirming their fit into known ontological pathways.

To determine the functional validity of the SNPs in the cluster, we attributed SNPs to their related genes (*n* = 57) and evaluated relevance to several phenotypes that we thought may be expressed in the study cohort. Many individual SNPs were functionally specific for arthralgia‐like disease phenotypes. Others were associated with estrogen metabolism -- a finding that supports the hypotheses suggested by the *CYP21A* candidate studies. None of the SNPs in this cluster were attributable to *CYP21A* genes, which may be a component of faults in SNP and gene designation. Genes associated with pain sensitization were notable, a finding theoretically similar to the interests of Lintemans et al [10](#cam41256-bib-0010){ref-type="ref"}. Interestingly, genes associated with RA pathophysiology were relatively high in the cluster, suggesting a common biological pathway with AIA and in congruence with other findings implicating an inflammatory mechanism. One SNP in the cluster was closely aligned with inflammation.

Although we included internal cross‐validation in this study, the investigation was limited by small sample size and our inability to have an independent validation cohort. We believe that increasing the training sample will result in a more robust predictive accuracy. An independent validation cohort will be critical to understanding the true clinical meaningfulness and translatability of our findings. A prospective study is currently underway to address these shortcomings.

Nonetheless, we believe that this trial demonstrates the potential utility of an undirected, machine‐learning approach in the development of a predictive test for AIA risk. Such a personalized model in which at‐risk patients are identified prior to therapy start may help to minimize toxicity by prompting the early institution of preventative, therapeutic, or alternative interventions, and thus improve treatment adherence and disease outcomes.

Conflict of Interest {#cam41256-sec-0014}
====================

Disclosures outside the submitted work are noted. Stephen Sonis, Ohio State University (grants), Primary Endpoint Solutions LLC (equity), Biomodels LLC (employee), Inform Genomics (equity); Juan Luis Fernández‐Martínez Primary Endpoint Solutions LLC (consultant); Ana Cernea Primary Endpoint Solutions LLC (consultant); Enrique J. de Andrés‐Galiana Primary Endpoint Solutions LLC (consultant).
